Part,  Chapter, Paragraph

 1   II,     5.  8.Acr    |     European Respiratory Society~FEV1~forced expiratory volume
 2   II,     5.  8.  3    | expiratory volume in one second (FEV1)/vital capacity (VC) % <
 3   II,     5.  8.  3    |  proportion to severity based on FEV1. The total medical cost
 4   II,     5.  8.  3    |    expenditure for patients with FEV1 below 40% is represented
 5   II,     5.  8.  3(27)|          Severity:~Stage I:~Mild FEV1/FVC <0.70~FEV1 80% predicted~
 6   II,     5.  8.  3(27)|     Stage I:~Mild FEV1/FVC <0.70~FEV1 80% predicted~Stage II:~
 7   II,     5.  8.  3(27)|     predicted~Stage II:~Moderate FEV1/FVC <0.70~50% FEV1 <80%
 8   II,     5.  8.  3(27)|      Moderate FEV1/FVC <0.70~50% FEV1 <80% predicted~Stage III:~
 9   II,     5.  8.  3(27)|      predicted~Stage III:~Severe FEV1/FVC <0.70~30% FEV1 <50%
10   II,     5.  8.  3(27)|        Severe FEV1/FVC <0.70~30% FEV1 <50% predicted~Stage IV:~
11   II,     5.  8.  3(27)|  predicted~Stage IV:~Very Severe FEV1/FVC <0.70~FEV1 <30% predicted
12   II,     5.  8.  3(27)|       Very Severe FEV1/FVC <0.70~FEV1 <30% predicted or FEV1 <
13   II,     5.  8.  3(27)|        70~FEV1 <30% predicted or FEV1 <50% predicted plus chronic
14   II,     5.  8.  4    |     Neither a steeper decline of FEV1 nor an increased prevalence
15   II,     5.  8.  5    |      showed an increase of 47 ml FEV1, compared with a decrease
16   II,     5.  8.  5    |         with a decrease of 49 ml FEV1 among continuing smokers (